Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases
This study demonstrates that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity. When neurons were exposed to toxins that induce neuronal death, CNM-Au8 treatment promoted the survival of cells and preservation of neurite networks. To unravel the mechanisms underpinning the neuroprotective function of CNM-Au8, Professor
“The insights gained from this research provide, for the first time, important guiding principles for the rational design of a new class of gold-based catalytic therapeutic agents with energy metabolism-regulating and neuroprotective functions,” said
The publication is available via Open Access at https://onlinelibrary.wiley.com/doi/10.1002/smll.202304082.
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, beliefs, intentions or strategies regarding our future operations. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Media Contact Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact kgardner@lifesciadvisors.com 617-283-2856 |
Source:
2023 GlobeNewswire, Inc., source